BiotechTube

PGN-EDODM1

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy 1

Conditions

Myotonic Dystrophy 1

Trial Timeline

Dec 10, 2024 → Aug 1, 2026

NCT ID
NCT06667453

About PGN-EDODM1

PGN-EDODM1 is a phase 2 stage product being developed by PepGen for Myotonic Dystrophy 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06667453. Target conditions include Myotonic Dystrophy 1.

What happened to similar drugs?

0 of 2 similar drugs in Myotonic Dystrophy 1 were approved

Approved (0) Terminated (0) Active (2)
🔄Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
🔄DYNE-101 + PlaceboDyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07220603Phase 2Recruiting
NCT06667453Phase 2Recruiting

Competing Products

16 competing products in Myotonic Dystrophy 1

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
TideglusibAMO PharmaPhase 2
25
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
VX-670Vertex PharmaceuticalsPhase 2
42
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
39
SAR446268SanofiPhase 1/2
39
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
32
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
29
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
44
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
36
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
41
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
33
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
29
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1 for infusionPepGenPhase 1
19